I decay possess base damage clustered within 8 to 10 bases of the break and 39-phosphate (P) and 39-OH ends. This study examined the effect of such structures on NHEJ in in vitro assays employing either 125 I decay-induced DSB linearized plasmid DNA or structurally defined duplex oligonucleotides. Duplex oligonucleotides that possess either a 39-P or 39-phosphoglycolate (PG) or a ligatable 39-OH end with either an AP site or an 8-oxo-dG 1 nucleotide upstream (21n) from the 39-terminus have been examined for reparability. Moderate to severe end-joining inhibition was observed for modified DSB ends or 8-oxo-dG upstream from a 39-OH end. In contrast, abolition of end joining was observed with duplexes possessing an AP site upstream from a ligatable 39-OH end or for a lesion combination involving 39-P plus an upstream 8-oxo-dG. In addition, base mismatches at the 21n position were also strong inhibitors of NHEJ in this system, suggesting that destabilization of the DSB terminus as a result of base loss or improper base pairing may play a role in the inhibitory effects of these structures. Furthermore, we provide data indicating that DSB end joining is likely to occur prior to removal or repair of base lesions proximal to the DSB terminus. Our results show that base damage or base loss near a DSB end may be a severe block to NHEJ and that complex combinations of lesions presented in the context of a DSB may be more inhibitory than the individual lesions alone. In contrast, blocked DSB 39-ends alone are only modestly inhibitory to NHEJ. Finally, DNA ligase activity is implicated as being responsible for these effects. g 2011 by Radiation
Research Society
INTRODUCTION
Radiation-induced DNA double-strand breaks (DSBs) have been implicated as potentially lethal events for a cell (1, 2) . Such lesions cause cell cycle arrest, and if unrepaired, they may result in cell death. However, even if rejoined, misrepaired DSBs may result in genomic instability and ultimately lead to the development of cancer (3) . The lethality of a DSB has been suggested to be dependent upon the complexity of the break, which in the case of radiation may depend on radiation quality with high-LET radiation, presumably creating DSBs of greater complexity than the majority of those produced by low-LET radiation (4) (5) (6) . High-LET radiation-induced DSBs appear to be less amenable to repair than those produced by other agents, and this has been proposed to reflect greater structural complexity and to explain their high relative cytotoxicity (4) (5) (6) (7) (8) (9) . Even for low-LET radiation-induced DSBs, it is the subset of breaks with high structural complexity that has been suggested to be most lethal (6, 8, 10, 11) . Consequently, it is the complex DSB, defined here as a double-stranded DNA discontinuity of variable overhang morphology with blocked ends and flanking base damage, that has been postulated to be the most critical DSB lesion.
DSBs resulting from exposure to various genotoxic agents, including ionizing radiation, are most commonly repaired by nonhomologous end joining (NHEJ). The core proteins involved in this pathway have been identified by genetic studies (12) (13) (14) (15) (16) as well as by in vitro assays [reviewed in ref. (17) ]. Numerous in vivo investigations (18) (19) (20) (21) (22) and cell-free in vitro assays have been employed to assess the roles of individual proteins in the NHEJ pathway, but it is the in vitro assays that have been most instructive with respect to the kinetics of the repair process and the biochemical functions of specific proteins in the repair pathway (17, 23) . In the case of in vitro assays designed to assess end joining of linear plasmid DNA as an end point for DSB repair, most have employed restriction enzyme-cut DNA as a substrate (24) (25) (26) (27) (28) (29) (30) (31) .
Although the NHEJ machinery can easily rejoin such substrates, the substrates themselves lack structural complexity and are a poor model for the complex DSBs typically produced by radiation and other genotoxic DNA-breaking agents such as enediyne drugs (32) . Consequently, in vitro assays using restriction enzymecut DNA do not allow for an understanding of the relationship between authentic DSB damage and the NHEJ machinery.
In our previous work, we described the molecular characteristics of the high-LET-like radiation-induced DSBs that result when 125 I decays in proximity to DNA (33) (34) (35) (36) . These DSBs are highly cytotoxic and are known to cause biological effects similar to those of high-LET beam radiation (37, 38) . At the molecular level, we have shown that 125 I decay-induced DSBs are extremely complex lesions that exhibit variable overhang end morphology (variable length 59 and 39 overhangs as well as blunt ends), ends that are largely blocked by 39-phosphate (39-P) and other groups but also occur with some 39-OH. We have also shown that these DSBs possess a high frequency of base damage and abasic sites immediately upstream from the DSB end.
Although in vitro repair studies have been conducted to investigate the importance of various restriction enzyme-induced end morphologies (i.e., overhangs and blunt ends) or end group structures on NHEJ (30, (39) (40) (41) and others have examined the effects of closely opposed base lesions in duplex DNA upon recognition and cleavage by base excision repair enzymes (42) (43) (44) (45) , it is still not clear how and to what extent various aspects of complex DSB structure affect and/or inhibit the DSB repair process. In a recent study by Dobbs et al. (46) it was shown that 8-oxoG positioned close to a DSB end was likely to interfere with base excision repair (BER) and was a poor substrate for processing by the purified human glycosylases hOGG1 and NEIL1. It was also shown that such lesions may inhibit ligation by T4 DNA ligase and purified Ligase IV/XRCC4 complex. These results illustrate the importance of examining what effect, if any, base damage and other lesions proximal to the DSB end have on NHEJ and what their relative effect on the repair process is with respect to the blocked ends that are formed by radiation and other DNAdamaging agents.
We have addressed this question by creating an in vitro synthetic oligonucleotide-based DSB end-joining assay in which each duplex oligo substrate contains defined lesions/modifications in association with the DSB end to be rejoined. The source of DSB repair enzyme activities for this assay is HeLa whole cell extracts. Using this repair system, we have compared the effects of 39-end blocking groups, upstream base lesions or apurinic/apyrimidinic (AP) sites on DSB repair with respect to the end-joining activity observed for equivalent substrates terminated by directly ligatable DSB ends. This work confirms observations by others that 39-blocking groups are a hindrance to repair with respect to unblocked 39-OH DSB ends (47) while further indicating that the presence of a base lesion 1 nucleotide upstream (21n) from a 39-OH terminated DSB end acts as a similar impediment to end joining. In contrast, as the structural complexity of the break is increased to contain a combination of a 39-end blocking group (39-P) with an 8-HO-dGua base lesion 21n from the DSB end, the endjoining reaction is completely blocked. Furthermore, DSB end structural configurations that may destabilize hydrogen bonding of the 39-end terminal nucleotide to its complement in the opposite strand, such as an AP site or a base mismatch 21n from the 39-end, also act as complete blocks to the end-joining reaction.
MATERIALS AND METHODS

Materials
Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum, nonessential amino acids (10 mM), glutamine (100 mM), penicillin/ streptomycin (10,000 U/ml), Saccharomyces cerevisiae tRNA, T4 DNA ligase and Novex TM 6% TBE gels were obtained from Invitrogen (Carlsbad, CA). Reagents for oligonucleotide synthesis were from Glen Research (Sterling, VA). Protease inhibitors and other chemicals were obtained from Sigma (St. Louis, MO). c-32 P-ATP (222 GBq/mmol) was obtained from Perkin Elmer Life Science (Boston, MA). T4 polynucleotide kinase (PNK) was from Fermentas (Hanover, MD). Escherichia coli endonuclease IV (endo IV), formamidopyrimidine DNA glycosylase (Fpg), and recombinant human DNA ligase IV/XRCC4 and Ku70/80 were from Trevigen (Gaithersburg, MD). Monoclonal anti-Ku70 (clone 2C3.11) antibody was from Novus Biologicals (Littleton, CO). Anti-DNA-PKcs (ab5366), anti-DNA ligase IV (ab6145), and anti-Ku80 (ab3107) antibodies were from Abcam (Cambridge, MA). The SequaGel sequencing system was obtained from National Diagnostics (Atlanta, GA). Protein assays were performed using the Bio-Rad system (Hercules, CA).
Plasmid
Plasmid pTC27 was a generous gift from Dr. Michael Seidman (NIA, Baltimore, MD). The plasmid possesses a polypurine sequence designed to permit binding of a pyrimidine-motif triple-helix-forming oligonucleotide (TFO). The features of this plasmid have been described in detail elsewhere (35) . The plasmid was grown in E. coli (DH10B) and purified with a Qiagen megaprep kit (Qiagen, Valencia, CA). Purified plasmid was quantified and purity checked by spectrophotometry and 1% agarose gel electrophoresis using a High Mass DNA ladder as the calibration standard (Invitrogen). I-dC was synthesized and purified as described previously (4, 34, 35) and used to form triplexes with pTC27. Plasmid linearized by TFO targeted 125 I decayinduced site-specific DSB formation was produced and characterized as described previously (4, 34, 35). As indicated in the previous work,
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irradiations were conducted in the presence or absence of 2 M DMSO by incubation of the triplex containing plasmids in 13 TFO binding buffer (30 mM CH 3 COONa, pH 4.5, 10 mM MgCl 2 , and 1 mM spermidine) at 280uC for 1 month.
Cell Extracts
HeLa cells were grown as monolayers at 37uC in DMEM containing 10% (v/v) fetal bovine serum, 1% (v/v) nonessential amino acids and 1% (v/v) penicillin/streptomycin. Cells were harvested by trypsinization and a representative flask was counted. Cells were washed two times by resuspension in complete medium followed by centrifugation at 800g for 5 min. The resulting cell pellet was washed two times with ice-cold PBS in a similar manner. The cells were resuspended in extraction buffer (10 mM Hepes, pH 7.9, 60 mM KCl, 1 mM DTT, 1 mM EDTA, 10 mM Pefabloc, 10 mg/ml aprotinin, 1.5 mg/ml leupeptin, 100 mg/ml bestatin) at a density of 8 3 10 7 cells/ml and lysed by the freeze/squeeze method using three cycles of freezing in a dry ice ethanol bath followed by immediate thawing at 37uC (48) . After the third thaw cycle, cell debris was removed by centrifugation at 16000g for 30 min at 4uC. The supernatant constituted the HeLa whole cell extract and was stored at 280uC in aliquots. Whole cell extracts of WI38 human fibroblast cells and human MO59K glioma cells were prepared in the same manner.
Plasmid-Based End-Joining Assay
End-joining reactions were typically conducted in a 50-ml total volume at 17uC overnight (16 h). Reactions contained 50 mM TrisHCl, pH 7.6, 5 mM MgCl 2 , 75 mM KCl, 1 mM ATP, 1 mM DTT, 5% polyethyleneglycol (PEG) 8000, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 10 mg/ml bestatin, 1 mM Pefabloc, 100 ng DSB terminated linear plasmid DNA (damaged in the presence or absence of 2 M DMSO), and HeLa whole cell extract (15 mg total protein per reaction). In control reactions, damaged DNA was replaced with StuI-cut plasmid, and in the case of positive controls, an end-joined plasmid ladder was formed by ligation with T4 DNA ligase ((1 U); 1 unit is defined as the amount of enzyme required to catalyze the exchange of 1 nmol of 32 PPi into [c/b-32 P]ATP in 20 min at 37uC). The repair reactions were stopped by the addition of SDS to 0.4% followed by incubation at 65uC for 15 min. The DNA was recovered by phenol-chloroform extraction followed by ethanol precipitation and resuspension in 5 ml TE, pH 8.0. The repair products were resolved in 1% agarose gels and stained with Vistra Green (Amersham Biosciences, Piscataway, NJ) at 1:20,000 dilution in TE buffer (pH 8.0) for 30 min at 4uC with gentle shaking. Digital images of the gels were obtained with a FluorImager 595 (Molecular Dynamics) and the data were analyzed densitometrically using GelPro 2.0 software (Media Cybernetics). The percentage yield of end-joined products was calculated as the sum of the end-joined DNA band densities divided by the sum of all DNA band densities times 100 ([(dimer z trimer z high-molecular-weight multimers)/(dimer z trimer z high-molecular-weight multimers z linear)] 3 100). In some cases, repair assays were supplemented with all four dNTPs (250 mM final concentration of each) and/or with XRCC4/DNA Ligase IV [10 U; 1 unit is defined as the amount of enzyme required to ligate oligo (dT) 24 when hybridized to poly (dA) 300 at the rate of 1 pmol in 30 min at 37uC].
Oligonucleotides
Five 75-mer oligonucleotides, and two complementary 79-mer oligonucleotides (Table 1) were synthesized on an ABI-394 DNA/ RNA synthesizer (Applied Biosystems, Foster City, CA) and band purified from 12% preparative denaturing PAGE gels. Prior to synthesis, the oligo sequences were analyzed to avoid secondary structures by using IDT SciTools OligoAnalyzer 3.0 (available at http:// scitools.idtdna.com/analyzer/Applications/OligoAnalyzer/). In the oligos containing base modifications, either an AP site (furan) or an 8-oxo-dG was positioned one nucleotide upstream from the 39-end of the 75-mer upper-strand oligo. The individual modifications incorporated into the 75-mer oligo (Table 1 , b-g) are labeled as follows: the bold p, pg, G* and @ indicate 39-phosphate (39-P), 39-phosphoglycolate (39-PG), 8-oxo-dG and the AP site, respectively. Oligos a and d are 39-OH terminated 75-mer controls, and oligos h and i are the 79-mer oligos that are either complementary to the 75-mers or can be used to form base mismatches at the 21n position of the upper strand 39-end when used in appropriate combinations with oligos a and e ( Table 2) . Oligo g will form a complex multiply damaged DSB end when annealed to oligo i. In the case of the 39-PG terminated 75 mer, oligonucleotide synthesis and postsynthesis chemistry were performed according to the method of Urata and Akagi (49) .
The presence of the modifications in the 75-mer oligos was confirmed by lesion-specific enzymatic treatment of 75-mer/79-mer Oligo h* has the same sequence as oligo h but is labeled at the 22n position from the 39-end (see Materials and Methods for labeling details) and possesses a nonradioactive PO 4 at its 59-end. duplex oligos in which the individual 75-mer oligos were typically 59-32 P-end labeled and subsequently tested for their ability to serve as substrates for appropriate enzymes. The presence and location of the AP site in oligo f was confirmed by cleavage with E. coli endo IV (1 U), while the 8-oxo-dG of oligo e was confirmed by cleavage with E. coli Fpg (1 U) after extension of the 39-end with exo 2 Klenow DNA polymerase (5 U). The presence of the 39-P in oligo b was confirmed by the ability of exo 2 Klenow polymerase to extend this oligo only after 39-phosphatase treatment with T4 PNK (10 U). The presence of 39-PG in oligo c was confirmed in two ways. Pretreatment of the duplex oligo with endo IV was required to permit extension of the 39-end by exo 2 Klenow polymerase (no extension was observed after 39-phosphatase treatment with T4 PNK), and production of a 25-mer oligo with a migration pattern characteristic of 39-PG was observed by 20% denaturing PAGE after TaqI restriction enzyme digestion of the duplex oligo and 59-32 P-end labeling.
Oligonucleotide-Based End-Joining Assay
As described previously (50), we developed an in vitro NHEJ assay based on a 75-bp duplex oligonucleotide with a 4-base 59 overhang (a 75-mer upper strand and a 79-mer lower strand) as an end-joining substrate. As employed here, the 79-mer strand is either 59-end labeled by c-32 P-ATP using T4 PNK (10 U) in the forward reaction (10 pmol oligo in 50 mM Tris-HCl, pH 7.6, 10 mM MgCl 2 , 5 mM DTT, 0.1 mM spermidine, 0.1 mM EDTA, and 2.22 MBq c 32 P-ATP in 10 ml reaction volume at 37uC for 45 min) or P end labeled by extension of a 4 base 39-shortened version of the 79-mer strand by using exo 2 Klenow DNA polymerase (5 U)-mediated incorporation of a-32 P-dCTP in the presence of TTP and dATP. Klenow-mediated 39-end labeling results in incorporation of a single a-32 P-dCTP 2 nucleotides upstream from the fully extended 39-end of the 79-mer strand, and we have designated this modification as oligo h*. To form duplexes, equimolar amounts of the appropriate 32 P-labeled 79-mer and cold 75-mer are mixed in 10 mM Tris-HCl, pH 8.0, in a reaction volume of 20 ml, incubated at 90uC for 5 min, and allowed to gradually cool to room temperature. The resulting duplex oligonucleotide possesses an end with a 4-base complementary 59-overhang and a nonligatable blunt end in which both the 39-and the 59-ends are OH. Duplex formation was confirmed by 6% nondenaturing PAGE (data not shown). The end-joining reaction using these substrates was essentially similar to the plasmid-based assay except that the reaction volume for the oligonucleotide assay was 10 ml and incubation was 30 min at 17uC followed by enzyme inactivation at 65uC for 15 min. Positive control reactions used 0.2 U T4 DNA ligase. The reaction products were then immediately loaded onto 6% nondenaturing or 8% denaturing PAGE gels as indicated in the figure legends.
EMSA
Electrophoretic mobility shift assays (EMSA) were performed as described previously for the undamaged duplex substrate (50) to determine the ability of the damage-bearing duplex oligonucleotides to support NHEJ protein-complex formation. To generate a supershift upon electrophoresis in 6% nondenaturing PAGE gels, anti-Ku 70 (2 ml), anti-DNA PK cs (2 ml), or anti-DNA ligase IV antibodies (2 ml) were added to individual reaction mixtures (20 ml) after addition of the cell extract (15 mg). Gels were visualized with a Fuji BAS-2500 phosphoimager and analyzed using FujiFilm Image Gauge v3.45 software.
RESULTS
Complex DSB End Joining by Human Cell Extracts
To determine what aspect of the DSB structure, as exemplified by the structures associated with the high-LET-like radiation-induced DSBs produced by 125 I decay (39-end structure or other lesions upstream of the DSB end), affects the ability of NHEJ to process the break and end-join the complex-DSB-terminated linear plasmids, we initially examined the ability of HeLa cell extracts to end-join 125 I-TFO linearized plasmid DNA that either had undergone T4 PNK 39-phosphatase treatment or were left untreated prior to end joining.
DNA from both (z) and (2) DMSO samples were subjected to HeLa cell extract-mediated end-joining assays (Fig. 1) . Both irradiation conditions produce highly complex DSBs with nearly equal amounts of base loss (AP sites) proximal to the break ends, and although substantial under both conditions, up to about twofold greater yields of oxidative base lesions occur in this region after irradiation in the absence of DMSO (33, 34) . Furthermore, while both irradiation conditions result in DSBs with variable overhang structures, T4 PNK 39-phosphatase treatment of (z) DMSO samples converts up to 92% of the DSB 39-ends to 39-OH, whereas similar treatment of (2) DMSO samples results in conversion of only 33% of DSB ends to 39-OH (36) . Therefore, even though the HeLa cell extract is expected to possess hPNK 39-phosphatase activity and should be capable of dephosphorylating DSB 39-ends, to ensure 39-dephosphorylation of the damaged plasmids prior to end joining, the substrates were pretreated with T4 PNK. In contrast to our previous T4 DNA-ligasemediated direct ligation results (36), 39-phosphatase treatment prior to the end-joining reactions did not alter the yield of end-joined products formed by the HeLa cell extract with either substrate. Furthermore, the product yields were small for both DNA samples, with only 6% of the (z) DMSO sample (Fig. 1A , upper panel lanes 3 and 5, and 1B, gray bars) and 3% of the (2) DMSO sample (Fig. 1A , lower panel, lanes 3 and 5, and 1B, black bars) converted to end-joined products regardless of the 39-phospatase pretreatment conditions. Therefore, although these DSBs are theoretically capable of being directly ligated to a large extent, and the HeLa cell extract was capable of efficiently end-joining StuI restriction enzyme-induced blunt ends (Fig. 1A and B, lanes 1), the extract could not efficiently end join the complex DSBs. One possible explanation for these results may be a deficiency in the repair reactions, such as a need for additional dNTPs to support DNA polymerasemediated fill-in reactions, or, as has been reported by others (51), the HeLa cell extract might have low DNA ligase IV levels even though it is capable of efficiently end joining the restriction enzyme-induced DSBs. Alternatively, these results may indicate that the 39-end blocking groups of the DSB are not the primary DSB structural feature that is impeding end joining but that other structural features, such as upstream base damage/loss, may be responsible for the blockage of end joining by the extract. To address the possibility that the poor end-joining efficiency exhibited by the HeLa cell extracts for the complex-DSB-terminated plasmid may be a function of cofactor or DNA ligase availability, the end-joining reactions were modified to include additional dNTPs to further support DNA polymerase-mediated fill-in reactions ( Fig. 2A) , recombinant human DNA ligase IV/ XRCC4 complex, or both (Fig. 2B) . Since the damaged plasmid from the (z) DMSO samples was somewhat more amenable to end joining by the HeLa cell extract than was the (2) DMSO DNA sample (Fig. 1) , this DNA was chosen to test these modifications of the reaction conditions.
As shown in Fig. 2A , addition of 250 mM of each dNTP (dGTP, dATP, dCTP and TTP) to the repair reactions resulted in only a marginal increase in endjoined product over reactions performed without dNTP addition. This result indicates that the paucity of end joining by the HeLa cell extract with this substrate (in comparison to the level observed with the StuI restriction enzyme-cut substrate) is not due to the need for a DNA polymerase-mediated fill-in step during or prior to the end-joining reaction.
To determine whether the low end-joining efficiency was due to an inadequate level of DNA ligase IV activity and/or a concomitant lack of dNTPs to support DNA polymerase activity, reactions were run with the addition of these components (Fig. 2B) . Addition of 10 U of recombinant human DNA ligase IV/XRCC4 complex to the HeLa cell extract-mediated end-joining reactions produced up to a 29% increase in end-joined product with the directly ligatable blunt ends of the StuI cut plasmid substrate. However, addition of the DNA ligase IV complex to end-joining reactions employing the damaged DNA substrate failed to enhance end joining more than a nominal amount, and further addition of dNTPs had no effect on the yield of product. Consequently, the inability of the HeLa cell extract to efficiently end join the complex DSBs of the damaged DNA substrate is not due to any of the known potential deficiencies of either the extract or the repair reaction conditions.
Taken together, these results suggest that rather than being an artifact or due to some deficiency in the whole cell extract, the poor end-joining efficiency of the damaged DNA is a function of DSB structure that is independent of the DSB end-group structure. Consideration of these results and the structural characteristics we have determined for the 125 I-induced DSB leads us to the hypothesis that base damage (including base loss) upstream but very close to a DSB end may have a greater impact upon the ability of the NHEJ pathway to rejoin the break than does DSB end-group chemistry.
The Effect of Upstream Base Damage Compared to Blocked 39-Ends on NHEJ
To compare the effects of base damage or base loss proximal to the DSB end with respect to 39 blocking groups at the DSB end on NHEJ, we modified our previously described in vitro duplex-oligonucleotidebased NHEJ assay (50) by incorporating the structurally defined oligonucleotides depicted in Table 1 . Individually annealing oligos a-g with oligo h, or in three cases i, forms a panel of nine 75-mer duplex oligonucleotides with 59-OH/39-OH blunt ends and an opposite-end lower strand with a 59-32 P-labeled self-complementary four-nucleotide overhang. The upper strand 39-ends of these duplexes are modified with a terminal blocking group or with a nucleobase alteration and/or a mismatch such that it occurs 21n upstream from the upper-strand 39-end. A combination of these structures may also be formed ( Table 2) .
The impact on the ability of HeLa whole cell extractmediated NHEJ to rejoin 39-blocked DSB ends in contrast to DSBs possessing ligatable 39-OH ends but with a damaged base, an AP site, or a damaged or undamaged base mismatch 21n from the DSB 39-end was assessed in repair reactions using the appropriately modified duplex oligo substrates. To determine the effect of 39-blocked ends on HeLa cell extract-mediated NHEJ, the extract's ability to end join the undamaged a/ h oligo duplex was compared to the yield of end-joined products in parallel repair reactions with the 39-Pblocked b/h oligo and the 39-PG-blocked c/h oligo ( Fig. 3A and Table 2 ). Although less than the T4 DNA ligase positive control (Fig. 3A, lane 2) , a substantial yield (,28%) of end-joined oligonucleotide dimers was typically obtained in reactions with the whole cell extract and the undamaged a/h oligo substrate (Fig. 3A, lane 3) . In contrast, the yield (,15%) of endjoined product from the 39-P-blocked b/h oligo was typically about half that formed with the undamaged a/h oligo (Fig. 3A, lane 5) . Furthermore, although the extract was capable of forming product with the 39-PG-blocked c/h oligo, end-joining activity with this substrate was even less than with the 39-P-blocked oligo (compare Fig. 3A, lanes 4 and 5) . These results are consistent with previous observations of NHEJ-mediated repair of 39-end-blocked DSBs (47, 52) , in which, as observed here, the blocked DSB ends are capable of supporting end joining but at a lower efficiency than directly ligatable DSB ends.
Although it is not a complete block to end joining, HeLa extract-mediated NHEJ is inhibited to a similar or even greater extent when the reaction is run using a duplex oligo substrate with ligatable 39-OH ends but with an 8-oxo-dG modification at the 21n position of the upper strand 39-end (duplex e/i; Fig. 3B , lane 5; also see Fig. 3G, lanes 5 and 6) . Furthermore, although the e/ i oligo duplex supports some direct ligation by T4 DNA ligase, the 21n 8-oxo-dG modification does appear to substantially inhibit its ligation (Fig. 3B , compare lane 2 and lane 4) but not to the same degree as the inhibition observed for HeLa extract NHEJ. In contrast, when presented with a duplex oligo substrate possessing an AP site at the 21n position of the upper strand's 39-OH end (duplex f/h), HeLa cell extract-mediated NHEJ is completely blocked (Fig. 3C, lane 5) . During quality control testing of the f/h oligo substrate, we demonstrated cleavage of the AP site by E. coli endo IV. Therefore, it was possible that the AP site in the f/h duplex might be cut by a HeLa cell extract AP endonuclease such as APE1 prior to initiation of the NHEJ ligation reaction; if so, this might account for the complete lack of end joining with this substrate if insufficient dNTPs were present in the extract to support DNA polymerase-mediated fill-in reactions subsequent to incision at the AP site. To test this, we supplemented the end-joining reaction with 250 mM of all four dNTPs. However, dNTP supplementation did not rescue whole cell extract-mediated end-joining activity for the 21n AP site oligo duplex substrate (Fig. 3C, lane 6) . Once again, although the 21n AP site duplex supported direct ligation by T4 DNA ligase, this modification was an even stronger inhibitor of direct ligation than was the 21n 8-oxo-dG lesion (Fig. 3C, lane 4) .
Unlike reactions involving the unmodified substrate, the AP site-modified substrate (and to a lesser extent the 21n 8-oxo-dG) appears to be susceptible to 59-dephosphorylation or degradation, as shown by the reduced signal of the substrate in Fig. 3C , lane 5, and this may mask dimer product formation since the yield of end-joined dimers would be expected to be proportionately less than the remaining unreacted oligo substrate. To differentiate between the inability of the HeLa cell extract to form end-joined products with the AP site-modified oligo duplex and simple loss of the 32 P label from the 59-end of the duplex's lower strand, endjoining reactions were run in which the 79-mer lower strand of the duplex was 32 P 39-end labeled by Klenow DNA polymerase extension as described in the Materials and Methods (oligo h*, Table 1 ). End-joining reactions employing the duplex formed between the 39-end-labeled lower strand and the AP site-modified upper strand (duplex f/h*) produced essentially identical results to those obtained with the 59-32 P end labeled duplex f/h substrate (compare Fig. 3D and C) . Furthermore, the end-joining reactions employing the 39-end-labeled lower strand indicated that the AP site-modified oligo duplex is not detectably exonucleolytically degraded by the HeLa cell extract (Fig. 3D, lane 6) ; therefore, the signal loss observed in the end-joining reactions using the 59-32 P end-labeled duplex lower strand is most likely due to loss of the 59-32 P label either through the action of a phosphatase or possibly as a result of 59-end trimming, which would be consistent with the known structure/ function characteristics of Artemis activity at 59-overhangs (53, 54) . Consequently, while 39-blocking groups have a negative impact on the ability of the human NHEJ pathway to rejoin a DSB, it appears that damage proximal to the DSB end may be an even greater obstacle for the NHEJ pathway to overcome.
Neither 39-P, 39-PG nor 21n 8-oxo-dG alone causes complete inhibition of HeLa cell extract-mediated NHEJ. However, based upon numerous reports (1, 8, 33, 36, 55, 56) , lesions such as these might be expected to exist concurrently in combination at complex radiationinduced DSBs and thus constitute a form of multiply I decay, at which such multiply damaged sites do exist, are largely unrejoinable by the human NHEJ pathway. Therefore, we sought to determine whether a multiply damaged DSB end consisting of a combination of lesions that are not complete blocks to NHEJ when presented individually at a DSB end might act as a stronger block to NHEJ when presented together. To test this, we employed the multiply modified g/i duplex oligo substrate (Table 2, Fig. 3E) . The g/i oligo duplex possesses an unligatable upper strand 39-P end in combination with a 21n 8-oxo-dG. This multiply damaged DSB structure acts as a complete block to end joining and is thus a more effective inhibitor of NHEJ than either modification alone when presented for end joining individually at a DSB end (Fig. 3E, lane 6 ). As expected, the g/i duplex does not support direct ligation by T4 DNA ligase due to its terminal 39-P (Fig. 3E, lane 5) .
Placement of 8-oxo-dG or AP site modifications at the 21n position of the DSB 39-end may act as an end destabilizer. Therefore, the inhibition observed during end joining of these DSBs may not reflect specific NHEJ responses to specific base lesion structures but may reflect a more generalized inability of the NHEJ pathway to efficiently join DSBs that possess unstable or poorly hydrogen-bonded and base-stacked configurations near the DSB end. To investigate this possibility, we generated two oligo duplex end-joining substrates (oligos e/h and a/i, Table 2 ) that possess mismatches at the 21n position from the DSB 39-end. Duplex a/i contains a mismatch between unmodified adenosine and cytosine bases at the 21n position of the upper strand 39-end, whereas oligo e/h contains a mismatch between a modified 8-oxo-dG and a thymine. T4 DNA ligasemediated direct ligation is considerably less efficient for the 21n 8-oxodG:T mismatch than it is for the A:C mismatch, suggesting that the mismatch containing the base lesion is more difficult to align and ligate (Fig. 3F , compare lane 5 and lane 8). Regardless of their ability to be directly ligated, neither mismatch substrate supports end joining by the whole cell extract (Fig. 3F, lanes 6  and 9) . The inability of both duplex e/h and a/i to support end joining by the HeLa cell extract suggests that destabilization of the DSB ends in these substrates may be a factor influencing inhibition of NHEJ, as opposed to the specific base lesion structure that is present near the DSB end.
To confirm that inhibition of NHEJ by base damage proximal to a DSB end is a broad-based property of NHEJ and not just an effect limited to HeLa cell extracts, freshly prepared whole cell extracts of HeLa, WI38 and MO59K cells were assayed for their ability to end join the e/i duplex containing 8-oxo-dG at the 21n position. Furthermore, to establish that the NHEJ inhibition observed to this point was not simply an effect of the terminal sequence of the substrate oligonucleotides used previously, reactions assessing the ability of the extracts to end join the e/i duplex were run in conjunction with the undamaged control duplex d/i, which contains the sequence matched canonical G:C Watson-Crick base pair at the 21n position of the upper strand 39-end (Fig. 3G) . End joining of the control duplex was efficient for all three whole cell extracts, ranging between ,30-40% (Fig. 3G, lanes 5, 7, and 9 ). In contrast, end joining by all three whole cell extracts was strongly inhibited ($80%) by 8-oxo-dG at the 21n position of the duplex (Fig. 3G, lanes 6, 8 and 10) . Furthermore, direct ligation of the 21n G:C base-paired d/i undamaged control duplex by T4 DNA ligase occurred at an efficiency similar to if not better than that of the 21n A:T base-pair-containing a/h undamaged control duplex (compare Fig. 3A-F, lanes 2, to  Fig. 3G, lane 3) . Again, as seen previously (Fig. 3B, lane  4) , the 8-oxo-dG containing e/i duplex only supported minimal amounts (,4%) of direct ligation by T4 DNA ligase (Fig. 3G, lane 4) .
Effects of Lesion Structures on Binding and Activity of HeLa Cell Extract Nonhomologous End-Joining Proteins on Damaged Duplex Substrates
We have previously shown that HeLa cell extractmediated dimer formation in the in vitro end-joining reaction with the unmodified a/h oligo duplex is a function of NHEJ, is dependent on Ku and is not simply a result of direct ligation (50) . To establish that the lesion modifications of our oligo duplex substrates do not interfere with the ability of the oligos to support binding and protein-complex formation by the NHEJ pathway core proteins, we conducted electrophoretic r terminated oligo duplexes. Lane 1, negative control; lane 2, T4 DNA ligase positive control; lanes 3-5, whole cell extract mediated reactions. Panel B: Typical end joining results for the 21n 8-oxo-dG e/i oligo duplex. Panel C: Typical end joining results for the 21n AP site f/h oligo duplex. Panel D: End-joining reactions complementary to those depicted in panel C, only employing the 39-32 P end-labeled lower strand in the a/ h* control, and f/h* 21n AP site-modified, oligo duplex substrates to assess for potential 59-32 P label loss in the previous experiments. Panel E: Typical end-joining results for the multiply damaged g/i duplex oligo structure containing a 21n 8-oxo-dG in combination with a 39-P blocked upper-strand 39-end. Panel F: Typical end-joining reaction results for assays using the mismatch oligo substrates exhibiting either a 21n A:C mismatch (duplex a/i) or a 21n mismatch involving the 8-oxo-dG base lesion opposite thymine (duplex e/h). Panel G: Typical end-joining results for the 21n 8-oxo-dG e/i oligo duplex (G*) matched with the d/i 21n G:C base sequence matched control (Ctrl) and whole cell extracts as indicated. In all panels, the ''d'' to the right of the gel indicates dimer end-joining products and the ''m'' indicates monomer substrate oligonucleotide.
INHIBITION OF DSB REPAIR BY DSB PROXIMAL LESIONS mobility shift/supershift assays (EMSAs) under the same conditions used previously with the a/h oligo.
The unmodified (duplex a/h) or damage-containing duplex oligos (duplexes e/i or f/h; 10 pmol/reaction) were permitted to form complexes with HeLa cell extract proteins (15 mg) in either the presence or absence of antibodies to NHEJ core-pathway protein components as indicated in Fig. 4A-C . All of the duplexes displayed mobility shifts in the presence of HeLa extract protein as well as antibody-specific supershifts after incubation with anti-Ku70, anti-DNA-PK cs or anti-DNA ligase IV antibodies. Similar results were obtained with EMSA assays in which the oligo duplexes contained 39-P or 39-PG blocked ends (data not shown). The demonstration of NHEJ core protein-dependent EMSA supershifts regardless of the duplex oligo substrate used in the EMSA reaction indicates not only that the 75-mer duplex oligo substrates are long enough to permit binding of these proteins but also that under our reaction conditions NHEJ protein complexes form on the oligos.
To further establish the role of the NHEJ pathway in this assay, end-joining reactions were performed with Ku80-immunodepleted HeLa cell extract. After immunodepletion, the yield of end-joined dimer products with the unmodified a/h and 39-P terminated b/h oligo duplexes was decreased (Fig. 4D) , and the reduction in   FIG. 4 . Electrophoretic mobility shift assays (EMSAs) and Ku80 immunodepletion effects. EMSAs were conducted as described in the Materials and Methods with the HeLa cell extract (WCE) and the 59-32 P end-labeled undamaged a/h oligo duplex (panel A), the 8-oxo-dG modified e/i oligo duplex (panel B), or AP site-modified f/h oligo duplex (panel C) as the protein-binding targets. The protein-bound duplex oligonucleotides were resolved in a 6% nondenaturing PAGE gel and data were obtained by phosphorimaging. Panel A is a compilation of data from two separate experiments as indicated by the vertical dashed line. In panels A-C, the letters to the right of the gel images represent the following: a identifies the position of the anti-Ku70 antibody mediated supershift; bands migrating between a and b in lanes 6 and 7 of panel A and lanes 4 and 5 of panels B and C are the anti-DNA-Pk cs and anti-DNA ligase IV supershift bands as indicated. The c indicates the position of the HeLa cell extract-mediated band shift, and d indicates the position of the unshifted duplex oligo targets. The functional effects of Ku80 immunodepletion on HeLa whole cell extract end joining was assessed as indicated in panel D using either the unmodified a/h oligo duplex or the 39-P terminated b/h duplex as the end-joining substrates. In this case, the ''d'' to the right of the gel indicates the end-joined dimer product and the ''m'' indicates the monomer substrate duplex.
product yield was proportional to the extent of Ku80 protein reduction in the depleted extract (data not shown). Taken together, demonstration of NHEJ pathway core-protein complex formation on the 75-mer duplex oligo substrates, along with inhibition of end joining after HeLa cell extract Ku80 immunodepletion, indicates that the oligonucleotide dimer products formed in the assay are produced via a Ku-dependent NHEJ reaction. This conclusion is further supported by results obtained by replacing HeLa whole cell extract in the oligo end-joining assay with purified recombinant Ku70/80 heterodimer and/or DNA ligase IV/XRCC4 tetramer (Fig. 5) . End joining of the unmodified a/h oligo duplex is supported only in the presence of both Ku70/80 and DNA ligase IV/XRCC4 (Fig. 5A, lane 5) , and DNA ligase IV/XRCC4 alone is not sufficient to support direct ligation of this duplex ( Fig. 5A and B, lane 3). Furthermore, when presented with the same 21n 8-oxo-dG (duplex e/i), 21n AP site (duplex f/h), and 21n 8-oxo-dG mismatch (duplex e/h) modified oligo duplexes used earlier, levels of dimer formation were observed that were consistent with and similar to those obtained for these substrates when the HeLa whole cell extract was used as the source of NHEJ proteins and enzyme activities (Fig. 5A-C) .
Temporal Sequencing of DNA Repair Events at the DSB End during NHEJ of Complex DSBs
As discussed above for HeLa whole cell extract mediated NHEJ of the f/h oligo duplex containing an AP site in the upper-strand 39-end at the 21n position, it appears that the AP site is not being incised and repaired by the BER proteins in the whole cell extract (Fig. 3C  and D) . This finding suggests that base lesions near the DSB end may still be present in the dimer products of the end-joining reaction. The continued presence of base lesions in the products of the NHEJ reaction would suggest that base damage processing may not be linked to NHEJ and does not occur concurrent with NHEJ but rather is an independent process, which if it occurs acts subsequent to the end-joining event. Thus the continued presence of base lesions in the end-joined dimer products of the NHEJ reactions employing oligo duplex e/i, in which 8-oxodG is positioned at the 21n position from the upper strand's 39-end, would indicate that the NHEJ reaction may take priority over BER in such structures. To test this, we subjected the e/i oligo duplex to the standard in vitro end-joining reaction using the HeLa whole cell extract as the source of NHEJ activities. The products of the end-joining reaction were then treated with E. coli Fpg to probe for the continued presence of the 8-oxo-dG modification (Fig. 6) . The HeLa whole cell extract was demonstrated to be active for NHEJmediated dimer formation (Fig. 6A and B, lanes 3 and  4) for both the unmodified control a/h oligo duplex and the 21n 8-oxo-dG modified e/i oligo duplex, and the dimer products of these reactions were susceptible to cleavage by Fpg, indicating the continued presence of the base lesion in the dimer products (Fig. 6A, lane 5) . Furthermore, addition of 250 mM of all four dNTPs did not rescue the BER reaction, nor did dNTP addition appear to rescue 8-oxo-dG removal prior to the NHEJ reaction and thus support subsequent dimer formation (Fig. 6B, lane 5) . All dimer products of the NHEJ reaction were equally susceptible to Fpg cleavage, suggesting that if BER occurs at this position, it occurs subsequent to the end-joining reaction and with the diminished kinetics that would be expected for such closely opposed base lesions (42, 45, (58) (59) (60) (61) .
DISCUSSION
The work presented in the current study was designed to determine what aspect(s) of the complex DSB structure induced by 125 I has the greatest impact on DSB repair and thus may be an important contributing factor to radiation cytotoxicity. The results presented here as well as those of previous studies (4, 57, 62) indicate that the high-LET-like radiation-induced sitespecific 125 I DSBs produced in our irradiation system are refractory to repair. The inability of HeLa whole cell extract to efficiently end join the 125 I-induced DSBs does not appear to be due to a cofactor or enzyme deficiency of the extract, since supplementation of end-joining reactions with either all four dNTPs or recombinant human DNA ligase IV/XRCC4 or both did not improve the end-joining ability of the extract (Fig. 2) . These results suggested that the poor end-joining activity of the HeLa cell extract for the 125 I-induced DSBs was not due to dNTP starvation of a DNA polymerase-mediated DSB repair step (63) (64) (65) or DNA polymerase-dependent secondary repair process such as BER. Furthermore, although our restriction enzyme-cleaved control DNA was efficiently end-joined by the whole cell extract, it has been reported by others that extracts of HeLa cells may be somewhat deficient in DNA ligase IV/XRCC4 complex and that this complex may also be involved in the polymerase-mediated gap-filling step of NHEJ (64, 66) . Therefore, we also conducted DNA ligase IV/ XRCC4 supplementation reactions. However, the endjoining activity of the supplemented reactions improved only marginally and did not approach the highefficiency end joining observed for the restriction enzyme-cleaved control DNA, nor did concurrent supplementation of dNTPs and DNA ligase IV/XRCC4 result in better end-joining activity than observed in their absence or with each component individually. These results suggest that the inability of the HeLa cell extract to support efficient end joining of the 125 Iinduced DSBs is not due to one of the known potential deficiencies of the extract but is a function of the DSB structure.
There are three basic categories of structural complexity that we have determined for 125 I-induced DSBs; these are DSB end morphology (i.e., DSB-end overhang configurations and polarities), DSB end-group structure (i.e., DSB-end terminal structures such as 39-P and 39-PG), and nucleotide damage in proximity to the DSB end. Our examination of end-group structure indicated that many of the DSB ends consist of either 39-OH or 39-P, particularly in DNA irradiated in the presence of 2 M DMSO. Furthermore, plasmid DNA linearized by 125 I decay supported direct ligation by T4 DNA ligase, and the yield of this reaction (8%) was significantly improved (to 45%) by prior T4 PNK 39-phosphatase treatment (36). These results not only indicated that the end-group structure of the 125 I-induced DSBs was relatively simple and might be expected to be capable of supporting ligation by the HeLa cell extract but also that the overhang morphology of the breaks was also not a major impediment to ligation. However, as we have shown, this is not the case. The 125 I-induced DSBs are refractory to NHEJ regardless of the reaction conditions or DNA pretreatments used. These results suggested that the base damage that occurs proximal to the 125 Iinduced DSBs might be a greater inhibitor of end joining than the DSB end structure or overhang morphology.
The question of which lesion structural configuration (damage upstream from the DSB end or blocked 39-ends) is most detrimental to DSB processing by the NHEJ machinery was addressed using the panels of defined duplex oligo nucleotide end-joining substrates 
108
shown in Table 2 . Our results indicate that a base lesion or base loss immediately upstream from the DSB end may be a more potent inhibitor of NHEJ than is an unligatable 39-end blocked by 39-P or 39-PG. Although a specific effect on NHEJ imparted by the lesion chemistry cannot be ruled out, our results may reflect an incapacity of the NHEJ system to efficiently process DSB ends that are unstable with respect to base pairing or base stacking. Such a conclusion is supported by the observation that an A:C base mismatch was equally inhibitory to the NHEJ reaction, as was a mismatch involving and 8-oxodG base lesion or an AP site at the same 21n position in the substrate. Thus lesions that would appear to prevent normal hydrogen bonding and/ or base stacking at or near the DSB end may be strong inhibitors of human NHEJ. Furthermore based upon the results obtained for direct ligation of such substrates with T4 DNA ligase (Fig. 3) as well as the similarity of the whole cell extract-mediated NHEJ results to those obtained with purified Ku and DNA ligase IV/XRCC4 ( Fig. 3 and 5 ), it appears likely that inhibition of the NHEJ reaction by the damaged DSB structures most probably occurs at the ligation step of the reaction and may reflect the ability/inability of DNA ligase IV/ XRCC4 to act on such structures.
Furthermore, the results of the temporal sequencing assay (Fig. 6 ) suggest that ligation of the DSB ends by DNA ligase IV/XRCC4 may be a prerequisite for repair of a base lesion in proximity to the DSB end. Thus base damage processing mechanisms that might be expected to reduce the DSB end complexity and result in increased DSB end-joining efficiency do not appear to be capable of effective activity prior to the ligation step of the NHEJ reaction. This is consistent with a recent study indicating that base lesions in proximity to a DSB end are poor substrates for purified human DNA glycosylases (46) . Similar results have been obtained in a plasmid-based system in which an AP site has been situated in a 2 nucleotide 59-overhang adjacent to the duplex terminus and juxtaposed to a blunt end at the opposite end of the plasmid (67) . After repair processing in human cells, although poorly repaired, nearly half of the products of this reaction involved a translesion synthesis mechanism and therefore retained the AP site in place during the end-joining process.
If there is in fact interaction between the NHEJ and BER pathways during the processing of complex DSB damage, our results seem to suggest that the presence of NHEJ pathway proteins bound to the DSB ends may further restrict access and the opportunity for BER proteins and other potential end-processing enzymes to act at DSB ends.
In contrast, in the context of clustered base lesions, where attempted repair of two closely opposed lesions could give rise to a DSB, the role of NHEJ in preventing DSB formation has already been examined. In one study (68) , it was found that NHEJ is only partially able to prevent conversion of clustered lesions to potentially lethal DSBs due to an incomplete or inaccurate repair carried out by Ku-dependent as well as Ku-independent pathways. Several other studies have suggested a role for the key components of the NHEJ pathway, especially the DNA-PK holoenzyme in the processing of non-DSB clustered DNA damage. This is in addition to the indirect role that DNA-PK cs exhibits in the regulation of expression for two key DSB processing proteins, ATM and Artemis (69) . Previous work had already suggested a potential role of the Ku heterodimer in the repair of closely opposed base lesions in DNA (70) . Recent work from the Georgakilas laboratory also describe a potentially important role for DNA-PK cs during the processing of oxidative base-lesion clusters in DNA. These studies (71, 72) demonstrate a significant decrease in processing of base-lesion clusters and enhanced cell death in the absence of DNA-PK cs or in the presence of chemically inactivated or partially deficient DNA-PK cs , indicating that it may have an important role in clustered base damage processing.
Such findings suggest that DNA-PK cs , and possibly other component proteins of the NHEJ pathway, may have complex multidimensional roles in the processing of structurally complex DNA damage. These proteins may be required for the processing of some classes of complex clustered base lesions, while in the case of the DSB lesions described here, they may be incapable of acting or possibly even interfere with and/or compete with proteins that might be required to process these DSBs into a reparable form. In support of this, our results suggest that the presence of NHEJ pathway proteins bound to the DSB ends may further restrict access and the opportunity for BER proteins and other potential end-processing enzymes to act at DSB ends.
Consequently, the exact interaction of DNA ligase IV/ XRCC4 with the damaged DSB structures as well as its precise role in the NHEJ inhibition observed with these DSB structures is of considerable interest for future studies, as is the exact nature of the damaged DSB structure required to induce strong inhibition of NHEJ (i.e., with respect to the sequence position and type of base lesion in relation to the DSB end).
Knowledge of the roles played by component structures of a complex DSB during the repair process may help us to better understand this process as well as some of the mechanisms that may underlie radiation cytotoxicity. This information may also provide insights supporting new approaches to enhance the effectiveness of radiation therapy by developing agents and/or methods that selectively increase the yield of those DSB-associated lesions that make the DSBs difficult to repair and hence are toxic to the cell. Alternatively, insights into these aspects of DSB structure-dependent inhibition of NHEJ may provide direction for the development of highly effective and specific small molecule inhibitors of human NHEJ that also might be used for therapeutic advantage in a wide range of cancer treatment protocols. Furthermore, understanding the biological consequences of critical complex DSB-lesion components may also be applicable to questions as diverse as establishing better risk estimates for long-duration space travel in which astronauts traveling beyond the Earth's magnetic field will be exposed to even greater doses of high-LET radiation than in low-Earth orbit (73) .
